Investigations were done to determine whether the replication kinetics of human immunodeficiency virus (HIV)-1 were altered when the virus acquired a set or subsets of five mutations (A62V, V75I, F77L, F116Y, and Q151M) in the pol gene conferring resistance to multiple dideoxynucleosides. In the absence of drugs, the replication rate of all infectious clones generated was comparable to that of wild type HIV-1. However, in the presence of zidovudine or didanosine, the comparative order for 
Investigations were done to determine whether the replication kinetics of human immunodeficiency virus (HIV)-1 were altered when the virus acquired a set or subsets of five mutations (A62V, V75I, F77L, F116Y, and Q151M) in the pol gene conferring resistance to multiple dideoxynucleosides. In the absence of drugs, the replication rate of all infectious clones generated was comparable to that of wild type HIV-1. However, in the presence of zidovudine or didanosine, the comparative order for replication was HIV-1 62 Human immunodeficiency virus type 1 (HIV-1) has proved 14]; however, these works examined HIV-1 variants only in the absence of drugs in vitro. A critical question yet to be to be capable of developing resistance against virtually any currently available therapeutic reverse transcriptase (RT) and proteanswered is whether such drug-resistant HIV-1 variants have replication capacity in the presence of drugs to which those ase inhibitors [1] [2] [3] [4] [5] [6] . In an attempt to delay or block the development of drug-resistant HIV-1 variants and alleviate drug variants are resistant. Therefore, we examined the replication kinetics of HIV-1 variants carrying multidrug resistance -assotoxicities, therapy with multiple antiviral drugs has been widely used [7, 8] . However, a set of five mutations in the pol gene, ciated mutations in the presence and absence of drugs, which including an AlajVal substitution at codon 62 (A62V), may help us to understand and predict the outcome of infection ValjIle at codon 75 (V75I), PhejLeu at codon 77 (F77L), with mutant HIV-1 and virus population changes after cessation PhejTyr at codon 116 (F116Y), and GlnjMet at codon 151 of or change in antiviral therapy. (Q151M), has been identified in HIV-1 isolated from patients receiving long-term combination chemotherapy with zidovudine plus zalcitabine or zidovudine plus didanosine; these mutations Materials and Methods confer on HIV-1 reduced sensitivity to multiple dideoxynucleoReagents and cells. Zidovudine and zalcitabine were pursides (ddNs) [9] [10] [11] [12] [13] . The frequency of the emergence of Q151M chased from Sigma (St. Louis) and didanosine from Calbiochem and its related mutations has been 3.5% to §19% in patients (San Diego). H9 and MT-2 cells were used to propagate HIVreceiving combination chemotherapy with multiple ddNs for ú1 mutations had comparable catalytic efficiency (k cat /K m ) comwere obtained from healthy HIV-1-seronegative donors by use of pared with that of wild type RT (RT wt ), although a marked ficoll-hypaque gradient centrifugation and were stimulated for 2-3 days with 10 mg of phytohemagglutinin M (PHA; Gibco-BRL, difference was noted in inhibition constants (K i ).
Grand Island, NY)/mL before use.
There are several reports describing replication kinetics of Construction of infectious HIV-1 clones. Infectious molecular HIV-1 variants resistant to multiple dideoxynucleosides [13, clones with mutations of interest were constructed by use of the pHXB2RIP7-based plasmid, pSUM9, as previously described [9, 11] . In brief, the XmaI and NheI sites were generated by introduc-by oligonucleotide-directed mutagenesis using the plus strand of formed data collected with each HIV variant propagated in the presence or absence of each antiretroviral agent (zidovudine or pTZNX1 as a template as previously described [9, 11] . To construct infectious clones, the XmaI-NheI fragment with mutations didanosine), by use of the nonlinear least squares method. The distribution of the residuals was tested and found to be consistent was subsequently transferred to pSUM9, generating infectious HIV-1 molecular clones with the intended mutations.
with normality. The F-like statistics for the comparisons of the two curves were calculated [17] . Because of the nonlinearity of Production of infectious HIV-1 clones. COS-7 cells were transfected with 15 mg of each molecular clone by the calcium the model, P values derived from the F distribution are only approximate. The Bonferroni correction was then applied to the 21 phosphate method (Promega, Madison, WI) according to the manufacturer's protocol. Infectious virions produced were harvested pairwise tests for each agent. It was assumed that the conservatism of this correction would account for any possible anticonservatism 48 h after transfection and were propagated in MT-2 cells and subsequently in H9 cells for 7-10 days. Culture supernatants obin the P values. tained were filtered through a 0.45-mm-pore membrane and stored at 070ЊC until use. Determination of the nucleotide sequence of the polymerase-encoding region of HIV-1 harbored in H9 cells
Results
confirmed that each infectious clone generated had the intended mutation(s) and no additional base changes in the polymeraseDrug susceptibility of infectious clones in the MAGI assay. with zidovudine plus zalcitabine or zidovudine plus didanosine as previously described [16] .
to multiple ddNs by use of Molt-4 or H9 cells as target cells
Determination of drug sensitivity. The sensitivity of infectious [9, 11] . Such culture assay systems, however, involve multiple MAGI assay, which involves only a single round of viral repliinoculum of each virus preparation (50 mL) that gave 100 blue cation [16] . In the 2-day MAGI assay, the integration of a cells/well was added, and the cells were further cultured in the single HIV-1 genome into the cellular DNA and subsequent presence of drugs. Eight to ten different drug concentrations (3- Tat protein expression result in the activation of the LTRfold serially diluted) were used at concentrations up to 100 mM Tat -driven reporter gene (b-galactosidase), which is visualized for zidovudine and zalcitabine and up to 300 mM for didanosine.
through the formation of blue cells [16] . Soluble CD4 (sCD4:
Forty-eight hours after virus exposure, all blue cells in each well 10 mg/mL) was initially added 16 h after virus exposure to were counted. All experiments were done in triplicate.
block the reinfection of the cells by newly produced virions;
Determination of the profile of viral replication. H9 cells (10 5 ) or PHA-stimulated PBMC (10 HIV-1 151 . Significances of the differences in IC 50 s compared by HIV-1 62/75/77/116/151 appeared to replicate somewhat more rapidly than other infectious clones. The data from the H9 culture were the Jonckheere-Terpstra method for trends were P õ .0001 for zidovudine, P Å .0079 for didanosine, and P Å .041 for zalcitacorroborated when PHA-stimulated PBMC were used as target cells ( figure 1B ). These data, taken together, agreed with our bine. Results of comparison of individual IC 50 s are shown in the legends to table 1.
previous data from steady-state kinetic studies showing comparable catalytic efficiency (k cat /K m ) for RT wt and RTs carrying These data show that the levels of reduced sensitivity of infectious clones to various ddNs are comparable to those detercombined mutations [15] . Q151M and T215Y mutations can coexist in RT. HIV-1 mined in the conventional assay [9, 11] and support that the five mutations in the pol gene account for the observed viral variants carrying all or subsets of the five mutations do not have a T215Y or T215F mutation associated with viral resistance to resistance to multiple ddNs.
HIV-1 replication in H9 cells in the absence of drugs. We zidovudine, except for a transient or sporadic appearance, despite long-term chemotherapy with zidovudine [9 -15] . It is attempted to compare the replication rate of each infectious clone in the absence of drugs. All infectious clones were titrated possible that a certain nucleotide or amino acid sequence(s) predisposes HIV-1 to the Q151M substitution and ultimately for their infectivity in the 2-day MAGI assay. H9 cells were exposed to an equal virus inoculum for each infectious clone the rest of the five mutations. It is also possible that once HIV-1 acquires Q151M, T215Y or T215F no longer occurs because that gave 1000 blue cells in the MAGI assay and were cultured in the absence of drugs. Since the MAGI assay involves 2 days of inconsistency. Another possibility is that there may be no selective advantage for HIV-1 151 to acquire an additional mutaof culture, then if the cells were infected with HIV-1 at the same infectious dose, the accumulated amount of newly protion in codon 215. We found that an infectious clone carrying both Q151M and T215Y (HIV-1 151/215 ) replicated as efficiently duced virions should be the same at the end of day 2 of culture, assuming that the level of replication of each virus preparation as HIV-1 wt (figure 2), and its drug sensitivity profile was comparable to that of HIV-1 215 (table 1), suggesting that the two was comparable in CD4-LTR/b-gal cells and H9 cells. The p24 Gag protein production by H9 cells exposed to HIV-1 151 , mutations do not impair the replicative ability of HIV-1.
Replication rates of HIV-1 variants in the presence of drug.
HIV-1 74 , or HIV-1 215 was comparable to that of HIV-1 wt , although HIV-1 215 was slightly delayed in its replication (figure In the clinical setting, the major driving force for drug-resistant HIV-1 variants to emerge is the selective advantage conferred 1A[a]). The p24 Gag protein production by H9 cells exposed to HIV-1 with a single mutation (HIV-1 62 , HIV-1 75 , HIV-1 77 , by high levels of viral drug resistance. We, therefore, exposed H9 cells to each infectious clone and cultured them in the HIV-1 116 , HIV-1 151 ) was comparable and also comparable with that of HIV-1 wt ( figure 1A[b] ). The Gag protein production by presence of zidovudine or didanosine. To completely inhibit the replication of HIV-1 wt , we chose 2 mM zidovudine and 10 H9 cells exposed to all or a subset of the five mutations figure 1A[c] ), although . replicated faster than did HIV-1 wt (P õ .05). There was also a significant difference between HIV-1 75/77/116/151 and thought to be the first mutation to develop [9, 12, 13] , followed by V75I, F77L, F116Y, and then A62V during therapy [9, 12] . HIV-1 62/75/77/116/151 (P Å .05) when propagated in the presence of didanosine ( figure 3B) .
In this regard, as seen in the case of HIV-1 resistant to a C 2 -symmetrical protease inhibitor (ABT-77003) [25] , once a It is noteworthy that the amount of Gag protein produced by H9 cells exposed to HIV-1 62/75/77/116/151 and cultured in the certain mutation occurs (in our case, Q151M), without regard to the presence or absence of drugs, HIV-1 may acquire other presence of zidovudine or didanosine reached ú300 ng/mL by day 10 of culture. This amount was comparable to that produe mutation(s) to improve virus infectivity and drug resistance. It has been noted that there is no viral acquisition of duced by H9 cells exposed to HIV-1 wt and cultured in the absence of drug ( figures 1A, 3) , suggesting that the replication zidovudine-associated mutations except transient or sporadic ones, despite long-term therapy including zidovudine [9 -13] rate of HIV-1 62/75/77/116/151 in the presence of zidovudine or didanosine was roughly comparable to that of HIV-1 wt in the ab-(Kavlick MF, Mitsuya H, unpublished data). The present data showed that HIV-1 151/215 had a level of resistance to zidovudine sence of drugs ( figures 1A, 3) . comparable with that of HIV-1 215 and propagated as efficiently as HIV-1 wt in the absence of drugs, suggesting that the two Discussion mutations do not impair the replicative ability of HIV-1 (table  1) . This is in agreement with our previous substrate analysis In the present work, we examine the relative viral replication kinetics of HIV-1 when it acquires a set or subsets of five data of RT carrying both mutations showing no significant difference in K m , k cat , and k cat /K m values between wild mutations (A62V, V75I, F77L, F116Y, and Q151M) in the pol gene conferring viral resistance to multiple ddNs [9 -14] . It type and Q151M-or T215Y-carrying RTs [15] . Iversen et al. [13] have also shown that the addition of T215Y to was possible, however, that in the conventional in vitro drug sensitivity assays [7, 18, 20 -22] , determinants of viral replica-HIV-1 75/77/116/151 did not change the replication profile of the virus. At present, it still remains to be determined whether HIVtion kinetics are masked during multiple cycles of viral replication (roughly 7 -10). In the present work, therefore, the 2-day 1 carrying Q151M can subsequently acquire the zidovudineassociated amino acid substitutions in patients receiving combi-MAGI assay using CD4-LTR/b-gal cells, which involves a single cycle of viral infection [16] , was used to assess the nation chemotherapy.
In this study, we also attempted to determine the replication difference in drug sensitivity. These data show that the levels of reduced sensitivity of infectious clones to various ddNs profile of each infectious clone carrying a single or combined mutations. When the p24 Gag protein production by H9 cells (table 1) were comparable to those determined in the conventional assay [9, 11] , supporting the notion that mutations in exposed to the same infectious titer adjusted by MAGI assay and cultured in the absence of drugs was used as an indicator the polymerase-encoding region account for the observed viral resistance to RT inhibitors. of viral replication, there was no significant difference for all infectious clones examined in H9 cells and PHA-stimulated The accumulation of multiple mutations associated with drug resistance does not occur at random but follows a certain order PBMC ( figure 1A[c] ). It should be noted that it is difficult to determine the replication kinetics of HIV-1 variants against in some cases [23, 24]. Among the five mutations, Q151M is that of wild type HIV-1. For example, Kellam et al. [24] have demonstrated that mutations at codons 41, 67, 70, and 215 produced a highly zidovudine-resistant phenotype; however, the addition of the mutations at codon 219 produces no detectable changes in the virus's sensitivity to zidovudine or in the replication characteristics. On the other hand, Caliendo et al. [26] have observed that HIV-1 carrying four zidovudine-associated mutations (HIV-1 67/70/215/219 ) had a replication advantage over wild type HIV-1 when target PBMC were stimulated with PHA after virus exposure and examined in the absence of drugs, but there was no discernable difference when PBMC were stimulated with PHA before virus exposure.
Van Rompay et al. [27] have recently isolated a mutant simian immunodeficiency virus (SIV mac ) carrying Q151M from macaques receiving prolonged zidovudine treatment and administered its molecular clone but not zidovudine to newborn macaques. All animals showed persistent viremia with a magnitude comparable to that seen in animals infected with wild type SIV. These results suggest that the Q151M mutation in SIV does not significantly impede the replication competence or pathogenicity and is genetically stable. In this respect, the amino acid at codon 151 (Gln) is located in the highly conserved concatenated motif B, which has been identified in the RT of animal and human retroviruses [28] . In fact, the pol genes from 16 animal and human retroviruses encode a Leu- the function of RT, in agreement with our present and previous data [6, 15] .
In this study, the most drug-resistant virus was HIV-1 75/77/116/151 , in the presence of drugs. However, with one or three mutations, but the replication rate of this clone was much slower than the virus acquires resistance, represented by higher IC 50 values, that of HIV-1 62/75/77/116/151 and slower even than that of and acquires partial but reasonable replicative capability in the HIV-1 77/116/151 (figure 3). In this regard, in 5 of 7 patients in presence of drugs. our study whose HIV-1 developed the Q151M mutation, all five mutations were identified, while HIV-1 of 2 patients devel-
